Li-Fraumeni syndrome

Hereditary Cancer Panel

10900 S Clay Blair Blvd, Suite 1400Olathe, KS - 66061

www.intelligene-cg.cominfo@intelligene-cg.com

Phone: 913 258 2300

IntelligeneCGsm Cancer Genomics is a laboratory specialized in cancer genomics.

IntelligeneCG’s team of highly qualifi ed professionals, with specialized experience in genomics, allows us to confi dently offer our clients comprehensive, accurate and detailed reports for all of our tests. Reports are available to providers quickly via our HIPAA compliant portal. Our tests and reports are developed to help medical teams create effective personalized screening and treatment plans for their patients. Each hereditarygenetic testing report is interpreted by a genetic coun-selor in order to ensure quality, answer questions and create an easy-to-understand report. What sets IntelligeneCGsm apart?

• IntelligeneCG’s test portfolio includes the Hereditary Genetic Testing (12 specifi c panels, single-site testing (familial mutations), exome testing, and the Prosigna Breast Cancer Prognostic Gene Signature Assay (FDA approved);• Quick and easy methods for collection of samples;• IntelligeneCG reports are clear and easy-to-under-stand, and are delivered to the ordering providers via a HIPAA compliant portal;• IntelligeneCG provides free of charge pre and post-test genetic counseling for all the patients being tested for hereditary cancer syndromes;• Providers can speak with our genetic counselor at any time with questions related to hereditary tests or reports;• Streamlined billing process and affordable payment plans.

Visit our webpage and get to know our complete portfolio of tests: www.intelligene-cg.com

Li-Fraumeni Syndrome

Li-Fraumeni is a rare cancer syndrome in which children and adults are at a high risk of developing cancer. Most common cancers in Li-Fraumeni syndrome include early-onset breast cancer, bone cancer (osteosarcoma), cancer of soft tissues (soft tissue sarcoma), brain tumors, leukemia and adrenocortical carcinoma. The exact prevalence of Li-Fraumeni syndrome is unknown, but is estimated to be 1 in 5,000 to 1 in 20,000. Approximately half of individu-als with Li-Fraumeni syndrome develop cancer by age 30; 90 percent develop cancer by age 60. Also, 15 percent of people with Li-Fraumeni syndrome develop second can-cer, 4 percent develop third cancer and 2 percent develop fourth cancer in their lifetime.

Red Flags for Li-Fraumeni Hereditary Cancer • Personal history of or a first degree relative with breast cancer diagnosed before age 30• Personal history of or a first degree relative with an adrenocortical tumor• Personal history of or a first degree relative with a cho-roid plexus tumor• Sarcoma diagnosed under age 18• Two or more close relatives with a tumor in the Li-Fraumeni Syndrome (LFS) spectrum, one diagnosed at or before age 45• Personal history of two or more LFS associated tumors, one diagnosed at or under age 45

Also, individuals who do not know their family medical his-tory (for example, if they were adopted) may be appro-priate candidates for genetic testing. Ask your healthcare provider if hereditary cancer genetic testing is right for you. Please contact your healthcare provider if hereditary can-cer genetic testing is right for you and to explore which IntelligeneCG hereditary cancer panels you may qualify for.

Benefits of Genetic Testing Hereditary cancer genetic testing may determine which in-dividuals were born with a predisposition to cancer. Know-ing the specific gene that is affected may provide informa-

tion regarding cancer risks as well as potential cancer screening and health management recommendations. Ge-netic testing may help to prevent cancer or aid in early diagnosis. For example, a woman who is aware of her high risk of developing uterine cancer may choose to have sur-gery to remove her uterus or increase her screening ex-ams/tests. Also, if a person has a known hereditary cancer predisposition, his or her biological relatives can get tested to see if they carry the same predisposition.

Testing ProcessThe hereditary cancer genetic test may be done on a saliva or blood sample. The sample is collected in a special kit and sent to the IntelligeneCG laboratory. Test results are sent to the ordering healthcare provider once they be-come available. If you have questions about genetic testing or your genetic testing results, you may contact the labora-tory before and/or after you find out your test results.

A genetic counselor at IntelligeneCG laboratory is available to discuss potential benefits and drawbacks to genetic testing, the meaning of the test results, follow-up steps and which family members may benefit from testing. Each patient can have one pre- and one post-testing con-sultation with the genetic counselor free-of-charge.

Genetic Testing and DiscriminationThe Genetic Information Nondiscrimination Act of 2008 (GINA), is a Federal law that prohibits discrimination in health coverage and employment based on genetic in-formation. GINA prohibits health insurers or health plan administrators from requesting or requiring genetic infor-mation of an individual or the individual’s family members, or using their genetic information to make decisions regar- ding coverage, rates, or preexisting conditions under most circumstances. GINA also prohibits many employers from discriminating against employees based on their personal genetic information. However, GINA does not protect in-dividuals from being discriminated in regards to life insu- rance, disability insurance and long-term care insurance.

Many states have their own laws to protect individuals from being discriminated in health insurance and employ-ment situations based on their genetic information. Each state has to offer, at a minimum, the same protections as GINA. Additional information about GINA may be found on website: https://www.genome.gov/10002328.

Additional information about GINA may be found on website: www.genome.gov/10002328

References:Genetics Reference: www.ghr.nlm.nih.gov/condition/li-fraumeni-syndrome#resourcesGeneReviews: www.ncbi.nlm.nih.gov/books/NBK1311/

Competitors - Overall Comparison

Multiple Technologies

Broader Test Availability

Short TAT

Focused Cancer Knowledge

CLIA Certified

Hereditary Cancer Panel

Tumor Panel

Comprehensive Report

Customized Tests

R&D

Provider & Patient Support

Breast Cancer Prognosis Testing (Prosigna)

Genetic Counseling

Criteria

Mos

t of

Com

petit

ors